Precigen (PGEN) In Focus As Russell Removal Tests Its Undervalued NarrativeSimplywall·Jul 9 at 02:57 PMPGEN-1.20%
Precigen CEO Helen Sabzevari disposes of 346,836 common shares worth $2,042,858.04PUBT·Jul 1 at 05:20 PMPGEN-1.20%
Precigen shareholders approve 7 million-share increase to 2023 incentive plan at annual meetingPUBT·Jun 24 at 03:08 PMPGEN-1.20%
Precigen, Inc. $PGEN Holdings Increased by Occam Crest Management LPMarket Beat·Jun 16 at 05:39 AMPGEN-1.20%BCS-5.65%
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging | PGEN Stock NewsStockTitan·Jun 14 at 09:40 PMPGEN-1.20%
Top Biotech Gainers: VRXA Begins A New Chapter, ADIL Opens Wallet, PGEN, PCSA On Watch...rttnews·Jun 11 at 10:59 PMVRXA-1.09%PGEN-1.20%
Precigen (NASDAQ:PGEN) Share Price Crosses Below 200-Day Moving Average - What's Next?Market Beat·Jun 9 at 03:17 AMPGEN-1.20%BNPQY+0.34%
Gilead Sciences Faces Potential Threat From In Vivo CAR-T, RBC SaysFidelity·Jun 8 at 10:00 AMGISGILD+3.22%
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years | PGEN Stock NewsStockTitan·May 30 at 05:35 AMPGEN-1.20%LABU-4.03%
